mRNA 1345
Alternative Names: mRNA-1345; Respiratory syncytial virus vaccine - Moderna TherapeuticsLatest Information Update: 29 Mar 2024
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Respiratory syncytial virus infections
- Phase I Metapneumovirus infections
Most Recent Events
- 27 Mar 2024 Updated immunogenicity data from the phase-III ConquerRSV trial in Respiratory syncytial virus infections released by Moderna Therapeutics
- 28 Feb 2024 Moderna completes a phase I clinical trials in Respiratory syncytial virus infections (Prevention) in USA, Australia and United Kingdom (IM) (NCT05585632) (EudraCT2022-002138-15)
- 22 Feb 2024 FDA assigns PDUFA action date by end of May 2024 for mRNA 1345